Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.

被引：50
|
作者：
Sullivan, Ryan J.
Hong, David S.
Tolcher, Anthony W.
Patnaik, Amita
Shapiro, Geoffrey
Chmielowski, Bartosz
Ribas, Antoni
Brail, Les H.
Roberts, Jennifer
Lee, Lucy
O'Connell, Brenda
Kutok, Jeffrey Lorne
Mahabhashyam, Suresh
Ullmann, Claudio Dansky
Postow, Michael A.
Wolchok, Jedd D.
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] South Texas Accelerated Res Therapeut, San Antonio, TX USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA
[6] Infin Pharmaceut Inc, Cambridge, MA USA
[7] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.3013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3013
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 1/1b, first-in-human study of the PI3K-gamma inhibitor IPI-549 as monotherapy and combined with nivolumab in patients with advanced solid tumors
    Ribas, Antoni
    Hong, David
    Tolcher, Anthony
    Sullivan, Ryan
    Shapiro, Geoffrey
    Chmielowski, Bartosz
    Brail, Les
    Lee, Lucy
    Mahabhashyam, Suresh
    Ullmann, Claudio Dansky
    Postow, Michael
    Wolchok, Jedd
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [2] IPI-549-01-A Phase 1/1b, first-in-human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with nivolumab in patients with advanced solid tumors
    Tolcher, Anthony
    Hong, David
    Sullivan, Ryan
    Mier, James
    Shapiro, Geoffrey
    Chmielowski, Bartosz
    Ribas, Antoni
    Postow, Michael
    Pearlberg, Joseph
    Brail, Les
    Lee, Lucy
    Ullmann, Claudio A. Dansky
    Wolchok, Jedd D.
    CANCER RESEARCH, 2017, 77
  • [3] First-in-human study of PM14 in patients with advanced solid tumors.
    Vieito, Maria
    Aix, Santiago Ponce
    Paz-Ares, Luis G.
    Bahleda, Rastilav
    Massard, Christophe
    Agreda, Leyre
    Banus, Eva
    Fernandez, Cristian Marcelo
    Cristoveanu, Elena Y.
    Corral, Gema
    Llanero, Lourdes
    Lubomirov, Rubin
    Kahatt, Carmen Maria
    Fudio, Salvador
    Nieto, Antonio
    Cullell-Young, Martin
    Zeaiter, Ali Hassan
    Oberoi, Honey Kumar
    Garralda, Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] IPI-549-01-A phase 1/1b first in human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with pembrolizumab in subjects with advanced solid tumors
    Tolcher, Anthony W.
    Hong, David S.
    Sullivan, Ryan J.
    Mier, James Walter
    Shapiro, Geoffrey
    Pearlberg, Joseph
    Brail, Les H.
    Kharidia, Jahnavi
    Han, Lixin
    Ullmann, Claudio Dansky
    Stern, Howard Marvin
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] First in human phase. study of BMS-986299 as monotherapy and combined with nivolumab and ipilimumab in advanced solid tumors.
    Nelson, Blessie Elizabeth
    Sheth, Rahul
    Kelly, Karen
    Park, Haeseong
    Patel, Sandip Pravin
    McKinley, Derrick
    O'Brien, Shaun
    Palau, Josep Lluis Parra
    Piha-Paul, Sarina A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] IPI-549-01: A Phase I/Ib first in human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with an anti-PD-1 antibody in subjects with advanced solid tumors
    Tolcher, Anthony
    Hong, David
    Sullivan, Ryan
    Mier, James
    Shapiro, Geoffrey
    Pearlberg, Joseph
    Brail, Les
    Kharidia, Jahnavi
    Han, Lixin
    Ullmann, Claudio Dansky
    Stern, Howard M.
    Wolchok, Jedd D.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [7] First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors.
    Sands, Jacob M.
    Shimizu, Toshio
    Garon, Edward B.
    Greenberg, Jonathan
    Guevara, Ferdinand M.
    Heist, Rebecca Suk
    Kobayashi, Fumiaki
    Noguchi, Yutaka
    Okajima, Daisuke
    Tajima, Naoyuki
    Spira, Alexander I.
    Yamamoto, Noboru
    Lisberg, Aaron Elliott
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] First-in-human dose escalation study of oral ONC201 in advanced solid tumors.
    Stein, Mark N.
    Mayer, Tina M.
    Moss, Rebecca Anne
    Silk, Ann W.
    Chan, Nancy
    Haffty, Bruce George
    DiPaola, Robert S.
    Beckett, Yasmeen
    Bentlyewski, Edward
    Zheng, Ling
    Fang, Bruno
    Allen, Joshua
    Mehnert, Janice M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors.
    Mehra, Ranee
    Camidge, D. Ross
    Sharma, Sunil
    Felip, Enriqueta
    Tan, Daniel Shao-Weng
    Vansteenkiste, Johan F.
    De Pas, Tommaso Martino
    Kim, Dong-Wan
    Santoro, Armando
    Liu, Geoffrey
    Goldwasser, Meredith
    Dai, David
    Radona, Marietta
    Boral, Anthony
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors.
    El-Khoueiry, Anthony B.
    Ning, Yan
    Yang, Dongyun
    Cole, Sarah
    Kahn, Michael
    Zoghbi, Marwan
    Berg, Jennifer
    Fujimori, Masamoto
    Inada, Tetsuhi
    Kouji, Hiroyuki
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345